Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate

Atsushi Ogino1, Genzou Takemura, Hiromitsu Kanamori

  • 1Second Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan.

Insights

Amlodipine improves survival and cardiac function after myocardial infarction by reducing cell death in the infarct zone. This calcium channel blocker may attenuate cardiac remodeling by inhibiting calcineurin and Bad activity.

Area of Science:

  • Cardiology
  • Pharmacology
  • Cell Biology

Background:

  • Left ventricular remodeling and dysfunction are common after myocardial infarction.
  • The precise mechanisms by which calcium channel blockers, such as amlodipine, prevent these adverse outcomes remain unclear.

Purpose of the Study:

  • To investigate the mechanism by which amlodipine attenuates post-myocardial infarction cardiac remodeling and dysfunction.
  • To explore amlodipine's effect on apoptosis and related signaling pathways in infarcted heart tissue.

Main Methods:

  • Myocardial infarction was induced in mice, followed by treatment with amlodipine, hydralazine, or saline.
  • Infarct size, cardiac function, cell apoptosis, and the expression/activity of calcineurin and Bad were assessed.
  • In vitro studies examined the effects of amlodipine and other inhibitors on myofibroblast apoptosis.

Main Results:

  • Amlodipine treatment improved survival and attenuated left ventricular dilatation and dysfunction post-myocardial infarction.
  • While infarct size was unchanged, amlodipine increased infarcted wall thickness and reduced apoptosis by inhibiting calcineurin and inactivating Bad.
  • Amlodipine, verapamil, nifedipine, cyclosporin A, and FK-506 inhibited Fas-mediated myofibroblast apoptosis in vitro.

Conclusions:

  • Amlodipine inhibits Fas-mediated apoptosis in granulation tissue cells within infarcted hearts.
  • This protective effect is likely mediated by the attenuation of calcineurin and Bad activities.
  • These findings offer new insights into the cardioprotective mechanisms of calcium channel blockers after myocardial infarction.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...